{"schema_version":"secwatch.filing_event.v1","accession":"0001641489-23-000019","form_type":"8-K","ticker":"VTVT","cik":"0001641489","company_name":"vTv Therapeutics Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.792707+00:00","generated_at":"2026-06-15T04:13:03.385101+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"vTv Therapeutics Q1 net loss narrows to $4.5M; cash rises to $18.8M; FDA agrees on pediatric study plan for TTP399","bullets":["Net loss attributable to vTv shareholders was $4.5M ($0.06/share) vs $7.0M ($0.10/share) in Q1 2022.","Cash and cash equivalents totaled $18.8M as of March 31, 2023, up from $12.1M at year-end 2022, after receiving $12M from G42 Investments.","R&D expenses increased to $3.9M from $3.1M YoY, driven by TTP399 development costs; G&A expenses decreased to $3.5M from $5.3M.","FDA agreed with pediatric study plan for TTP399 in type 1 diabetes patients aged 2-16; phase 2 study in type 2 diabetes on insulin therapy being prepared with G42 affiliate.","Revenue was $0 in Q1 2023 vs $2M in Q1 2022 (prior collaboration revenue ended)."],"urls":{"canonical":"https://secwatch.observer/filing/0001641489-23-000019","json":"https://secwatch.observer/filing/0001641489-23-000019.json","markdown":"https://secwatch.observer/filing/0001641489-23-000019.md","text":"https://secwatch.observer/filing/0001641489-23-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641489/000164148923000019/0001641489-23-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641489/000164148923000019/vtvt-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:13:03.385101+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"13af7b26acebfd91e1258f8c73e081c65c5c89f8","claim":"vTv Therapeutics Inc. reported the first quarter ended March 31, 2023 results: net income $4.5 million, EPS $0.06 per basic share.","evidence_excerpt":"Net loss attributable to vTv shareholders for the three months ended March 31, 2023, was $4.5 million or $0.06 per basic share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641489/000164148923000019/0001641489-23-000019-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Net income","value":"$4.5 million"},{"label":"EPS","value":"$0.06 per basic share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}